EN | UA
EN | UA

Help Support

Back

Vedolizumab is safe and effective to treat IBD elderly patients

Vedolizumab is safe and effective to treat IBD elderly patients Vedolizumab is safe and effective to treat IBD elderly patients
Vedolizumab is safe and effective to treat IBD elderly patients Vedolizumab is safe and effective to treat IBD elderly patients

A multi-center, observational, real-world cohort study was conducted to explore the safety and effectiveness of vedolizumab in biologically naive individuals with Crohn’s disease and ulcerative colitis.

See All

Key take away

Among elderly patients with IBD (inflammatory bowel disease), vedolizumab (humanized monoclonal antibody) was found to be safe and effective as a first-line biological. It displayed high rates of clinical response and steroid-free remission at both induction and maintenance.

Background

A multi-center, observational, real-world cohort study was conducted to explore the safety and effectiveness of vedolizumab in biologically naive individuals with Crohn’s disease and ulcerative colitis.

Method

From the cohort of the Sicilian Network for Inflammatory Bowel Disease (SN-IBD), the web-based data of consecutive biologically naive patients with Crohn’s disease and ulcerative colitis treated with vedolizumab from July 2016 to December 2019 were extracted.

The study recruited a total of 172 consecutive patients (Crohns disease: N=88; Ulcerative colitis: N=84; median age 66.0 years). Participants were followed for a median follow-up of 58.8 weeks.

Result

After 14 and 52 weeks, the percentage of patients reporting clinical response and achieving steroid-free remission is illustrated in the following table and figure:



CRP: C-reactive protein; CS: Clinical steroid

Conclusion

Vedolizumab may be used as a first-line biological, particularly among elderly IBD patients as it is safe and effective.

Source:

United European Gastroenterology Journal

Article:

Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study

Authors:

Fabio Salvatore Macaluso et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: